Heart Failure 2021

Mann, Douglas L.

doi:10.1161/circresaha.121.319391

Cited by 3 publications

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A recent HF compendium highlighted several translational successes, including the exciting prospects for SGLT2 inhibitors for heart failure with reduced ejection fraction (HFrEF) ( McMurray et al, 2019 ) or heart failure with preserved ejection fraction (HFpEF) ( Nassif et al, 2021 ), and tafamidis for transthyretin (TTR) cardiac amyloidosis ( Maurer et al, 2018 ); yet strikingly, only one of the therapeutic approaches covered in several HF compendia was translated into a new therapy for patients with HF ( Mann, 2021 ). The relative paucity of new drug classes for HF is rooted in our incomplete understanding of HF pathophysiology.…”

Section: Better Fundamental Understanding Of Human Hfmentioning

confidence: 99%

The grand challenge of discovering new cardiovascular drugs

Hong

2022

Front. Drug. Discov.

View full text Add to dashboard Cite

KEYWORDSdrug discovery, heart failure, human genetics, inherited cardiomyopathy, induced pluripotent stem cells, academia-biotech-pharma ecosystem, real world data, biobanking and biorepositories BackgroundHeart disease is the #1 killer worldwide, greater than all cancers combined. This is despite the fact that, in the developed world, there has been a substantial decline in cardiovascular mortality since the mid-20th century (Centers for Disease Control and Prevention (CDC), 1999), driven largely by a reduction in ischemic heart disease (Mensah et al., 2017;Nowbar et al., 2019). This decline is multifactorial, involving a reduction in tobacco use, changes in diet, treatment of hypertension, advances in rapid coronary revascularization, and the advent of β-hydroxy β-methylglutaryl-CoA (HMG-CoA) reductase inhibitors, and P2Y12 ADP receptor antagonists (Arnett et al., 2019). However, with the adoption of the Western diet and lifestyle in the developing world, and the rise in prevalence of cardiometabolic diseases and obesity, there has been an increase in the global burden of cardiovascular diseases (CVD) (Roth et al., 2020) and a stalling of improvements in the United States (Sinatra and Huston, 2020).Our collective success in treating cardiovascular diseases has been mixed. While the relative burden of ischemic heart disease (IHD) has decreased in the developed world, the burden of heart failure (HF) has increased in the past several decades (Virani et al., 2021). HF is now a global pandemic, afflicting 26 million people worldwide and 6 million in the United States alone (Savarese and Lund, 2017;Jackson et al., 2018). Despite advances in medical and surgical therapies, HF is associated with high mortality, having a lower 5years survival rate than most cancers (Virani et al., 2021). In fact, even as the mortality rate from IHD dropped 14.9% from 2011 to 2017, the HF mortality rate increased 20.7% during the same period (Sidney et al., 2019). Additionally, HF is associated with significant morbidity, reduced quality of life, and loss of earning potential due to diminished functional capacity. Moreover, advanced HF is frequently associated with anemia, sarcopenia, renal failure, depression, and cognitive decline (Lang and Mancini, 2007). Medical management is difficult and often complicated by volume overload and/or kidney injury. Consequently, HF is a leading diagnosis for hospitalizations and rehospitalization in the United States (McDermott and Roemer, 2021). Even as the advent of goal-directed medical therapy (GDMT) has substantially modified the rate of progression of HF, and internal cardiac defibrillators have reduced the risk of sudden cardiac death (van der Meer et al., 2019), HF remains a progressive disease, often

show abstract

Section: Better Fundamental Understanding Of Human Hfmentioning

confidence: 99%

The grand challenge of discovering new cardiovascular drugs

Hong

2022

Front. Drug. Discov.

View full text Add to dashboard Cite

show abstract

Advances in Injectable Hydrogel Strategies for Heart Failure Treatment

Zhang

Luo

et al. 2023

Adv Healthcare Materials

View full text Add to dashboard Cite

Heart failure (HF) affects 60 million people worldwide and has developed into a global public health problem surpassing cancer and urgently needs to be solved. According to the etiological spectrum, HF due to myocardial infarction (MI) has become the dominant cause of morbidity and mortality. Possible treatments include pharmacology, medical device implantation, and cardiac transplantation, which are limited in their ability to promote long-term functional stabilization of the heart. Injectable hydrogel therapy has emerged as a minimally invasive tissue engineering treatment approach. Hydrogels can provide the necessary mechanical support for the infarcted myocardium and serve as carriers of various drugs, bioactive factors, and cells to improve the cellular microenvironment in the infarcted region and induce myocardial tissue regeneration. Herein, the pathophysiological mechanism of HF is explored and injectable hydrogels as a potential solution for current clinical trials and applications are summarized. Specifically, mechanical support hydrogels, decellularized ECM hydrogels, a variety of biotherapeutic agent-loaded hydrogels and conductive hydrogels for cardiac repair were discussed, and the mechanism of action of these hydrogel-based therapies was emphasized. Finally, the limitations and future prospects of injectable hydrogel therapy for HF post MI were proposed to inspire novel therapeutic strategies.

show abstract